ArticleDermatology and therapy2024

Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: Analysis of the 3-Year Phase 3 Rising Up Study.

Norito Katoh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.